肺癌的分子病理 肺癌的分子病理
1Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard Unit 83, Houston, TX 77030, USA.
Clinics in laboratory medicine
|May 31, 2024
概括
精确的基因组测试可以确定肺癌的可操作目标,指导治疗选择. 病理学家需要对小肺癌样本进行分子测试的更新指南,以确保最佳的患者治疗.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 病理学 病理学 病理学
背景情况:
- 可针对性基因组改变对于指导肺癌治疗至关重要.
- 肺癌分子和生物标志物测试领域正在迅速发展.
- 病理学家在利用小型肺癌标本进行辅助分子测试时面临着挑战.
研究的目的:
- 强调识别肺癌中可向的基因组改变的重要性.
- 通知病理学家关于样本要求,测试方法和分子测试的关键目标.
- 强调指导语句在优化辅助分子测试中的作用.
主要方法:
- 审查目前关于肺癌分子测试的指导声明.
- 讨论在小型活检样本上进行辅助分子测试的最佳实践.
- 确定肺癌治疗选择的基本基因组标.
主要成果:
- 标准的护理需要识别可向的基因组改变,以便选择治疗.
- 病理学家需要了解临床决策的测试协议和目标.
- 现有的指导方针有助于最大限度地提高小肺癌样本的效用.
结论:
- 准确的基因组分析对个性化肺癌治疗至关重要.
- 遵守指导方针可确保在病理学中优化分子测试的使用.
- 有信息的测试实践可以为患者护理提供临床相关的基因组信息.
相关概念视频
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K


